Is elevated plasma homocysteine linked to higher risk of cardiovascular disease and cognitive decline?

Elevated plasma homocysteine (Hcy) is a well-characterized biomarker associated with vascular and neurodegenerative pathologies, presenting highly relevant implications for older adults.

Cardiovascular risk and the therapeutic paradox

• Strong observational link: Cohort studies establish elevated Hcy as an independent predictor of coronary artery disease and stroke. It drives vascular pathology by promoting endothelial dysfunction and oxidative stress.
• Neutral interventional trials: Large-scale randomized trials show that while B-vitamin supplementation (folic acid, B12, B6) effectively lowers Hcy, it does not reduce major adverse cardiovascular events or cardiovascular mortality. A modest reduction in stroke risk remains the only notable clinical exception, primarily in regions lacking mandatory dietary folate fortification.

Cognitive decline and brain atrophy

• Elevated dementia risk: Prospective studies link elevated Hcy to a 1.15- to 2.5-fold increased risk of developing Alzheimer’s disease and vascular dementia.
• Targeted therapeutic benefit: In individuals with mild cognitive impairment (MCI) and elevated baseline Hcy (>13 µmol/L), randomized controlled trials demonstrate that B-vitamin therapy slows the rate of accelerated brain atrophy by up to 50% and limits clinical cognitive decline.

Pathological mechanisms

• Excitotoxicity: Homocysteine acts as an agonist at NMDA receptors, triggering excessive calcium influx, mitochondrial impairment, and neuronal death.
• Neuropathology: High Hcy levels directly accelerate tau hyperphosphorylation and aggregation while driving blood-brain barrier disruption and cerebral microangiopathy.

Bottom line

• While lowering homocysteine does not translate to reduced coronary event rates, targeted B-vitamin supplementation is clinically indicated for older adults with mild cognitive impairment and elevated baseline homocysteine (>13 µmol/L) to significantly slow brain atrophy and delay cognitive decline.